

Polycystic Kidney Disease Drugs Market Size, Trends, Analysis, and Outlook By Type (ADPKD (Autosomal Dominant Polycystic Kidney Disease), ARPKD (Autosomal Recessive Polycystic Kidney Disease)), by Region, Country, Segment, and Companies, 2024-2030

https://marketpublishers.com/r/P7EB0F1B5BF8EN.html

Date: March 2024

Pages: 190

Price: US\$ 3,980.00 (Single User License)

ID: P7EB0F1B5BF8EN

Abstracts

The global Polycystic Kidney Disease Drugs market size is poised to register 6.24% growth (CAGR) from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Polycystic Kidney Disease Drugs market By Type (ADPKD (Autosomal Dominant Polycystic Kidney Disease), ARPKD (Autosomal Recessive Polycystic Kidney Disease)).

The future of polycystic kidney disease (PKD) drugs is characterized by advancements in targeted therapies, disease-modifying agents, and personalized medicine approaches to address the underlying pathophysiology, slow disease progression, and improve renal outcomes in patients with autosomal dominant PKD (ADPKD) and autosomal recessive PKD (ARPKD). Key trends include the development of novel pharmacological interventions targeting cystogenesis, renal fibrosis, and inflammation pathways, such as vasopressin receptor antagonists, mTOR inhibitors, and anti-fibrotic agents, to reduce cyst growth, preserve renal function, and delay the onset of end-stage renal disease (ESRD). Additionally, there is growing interest in combination therapies, gene-based therapies, and precision medicine strategies, including patient stratification based on genetic biomarkers, disease stage, and risk factors, to optimize treatment outcomes, minimize adverse effects, and tailor therapeutic interventions to individual patient needs. Moreover, there is increasing emphasis on patient-centered care, multidisciplinary management, and holistic approaches to address comorbidities, complications, and quality of life issues associated with PKD, driving innovation and collaboration across academia, industry, and patient advocacy groups in the field of PKD drug development...



Polycystic Kidney Disease Drugs Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Polycystic Kidney Disease Drugs market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Polycystic Kidney Disease Drugs survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Polycystic Kidney Disease Drugs industry.

Key market trends defining the global Polycystic Kidney Disease Drugs demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

Polycystic Kidney Disease Drugs Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Polycystic Kidney Disease Drugs industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Polycystic Kidney Disease Drugs companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Polycystic Kidney Disease Drugs industry

Leading Polycystic Kidney Disease Drugs companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The



report provides key strategies opted for by the top 10 Polycystic Kidney Disease Drugs companies.

Polycystic Kidney Disease Drugs Market Study- Strategic Analysis Review

The Polycystic Kidney Disease Drugs market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

Polycystic Kidney Disease Drugs Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Polycystic Kidney Disease Drugs industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

Polycystic Kidney Disease Drugs Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

North America Polycystic Kidney Disease Drugs Market Size Outlook- Companies plan



for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Polycystic Kidney Disease Drugs market segments. Similarly, Strong end-user demand is encouraging Canadian Polycystic Kidney Disease Drugs companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Polycystic Kidney Disease Drugs market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Polycystic Kidney Disease Drugs Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Polycystic Kidney Disease Drugs industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Polycystic Kidney Disease Drugs market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Polycystic Kidney Disease Drugs Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Polycystic Kidney Disease Drugs in Asia Pacific. In particular, China, India, and South East Asian Polycystic Kidney Disease Drugs markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and



comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

Latin America Polycystic Kidney Disease Drugs Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Polycystic Kidney Disease Drugs Market Size Outlookcontinues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Polycystic Kidney Disease Drugs market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Polycystic Kidney Disease Drugs.

Polycystic Kidney Disease Drugs Market Company Profiles

The global Polycystic Kidney Disease Drugs market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Apotex Inc, AstraZeneca Plc, Dr. Reddys Laboratories Ltd, Galapagos NV, Johnson and Johnson, Merck and Co. Inc, Novartis AG, Otsuka Holdings Co. Ltd, Palladio Biosciences Inc, Reata Pharmaceuticals Inc, Regulus Therapeutics Inc, Sanofi SA, Teva Pharmaceutical Industries Ltd, XORTX Therapeutics Inc.

Recent Polycystic Kidney Disease Drugs Market Developments

The global Polycystic Kidney Disease Drugs market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Polycystic Kidney Disease Drugs Market Report Scope



Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast

Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local

Currency)

Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

Market Segmentation:

By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

By Display

Color Ultrasound

B/W Ultrasound



By Portability

By Fortability
Trolley or Cart-Based Ultrasound Systems
Compact/Handheld Ultrasound Systems
Point-of-Pare (PoC) Ultrasound Systems
By Application
Radiology or General Imaging
Obstetrics or Gynecology
Cardiology
Urology
Vascular
Orthopedic and Musculoskeletal
Pain Management
Others
By End-User
Hospitals
Surgical Centers and Diagnostic Centers
Maternity Centers
Ambulatory Care Centers
Research and Academia
Others

Polycystic Kidney Disease Drugs Market Size, Trends, Analysis, and Outlook By Type (ADPKD (Autosomal Dominant...



Geographical Segmentation: North America (3 markets) Europe (6 markets) Asia Pacific (6 markets) Latin America (3 markets) Middle East Africa (5 markets) Companies Apotex Inc AstraZeneca Plc Dr. Reddys Laboratories Ltd Galapagos NV Johnson and Johnson Merck and Co. Inc Novartis AG Otsuka Holdings Co. Ltd Palladio Biosciences Inc Reata Pharmaceuticals Inc Regulus Therapeutics Inc Sanofi SA



Teva Pharmaceutical Industries Ltd

XORTX Therapeutics Inc

Formats Available: Excel, PDF, and PPT



Contents

1. EXECUTIVE SUMMARY

- 1.1 Polycystic Kidney Disease Drugs Market Overview and Key Findings, 2024
- 1.2 Polycystic Kidney Disease Drugs Market Size and Growth Outlook, 2021- 2030
- 1.3 Polycystic Kidney Disease Drugs Market Growth Opportunities to 2030
- 1.4 Key Polycystic Kidney Disease Drugs Market Trends and Challenges
- 1.4.1 Polycystic Kidney Disease Drugs Market Drivers and Trends
- 1.4.2 Polycystic Kidney Disease Drugs Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Polycystic Kidney Disease Drugs Companies

2. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE OUTLOOK TO 2030

- 2.1 Polycystic Kidney Disease Drugs Market Size Outlook, USD Million, 2021- 2030
- 2.2 Polycystic Kidney Disease Drugs Incremental Market Growth Outlook, %, 2021-2030
- 2.3 Segment Snapshot, 2024

3. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET- STRATEGIC ANALYSIS REVIEW

- 3.1 Porter's Five Forces Analysis
- * Threat of New Entrants
- * Threat of Substitutes
- * Intensity of Competitive Rivalry
- * Bargaining Power of Buyers
- * Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

4. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SEGMENTATION ANALYSIS AND OUTLOOK

- 4.1 Market Segmentation and Scope
- 4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030 By Type



Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

By Display

Color Ultrasound

B/W Ultrasound

By Portability

Trolley or Cart-Based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-Pare (PoC) Ultrasound Systems

By Application

Radiology or General Imaging

Obstetrics or Gynecology

Cardiology

Urology

Vascular

Orthopedic and Musculoskeletal

Pain Management

Others

By End-User

Hospitals

Surgical Centers and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Others

- 4.3 Growth Prospects and Niche Opportunities, 2023-2030
- 4.4 Regional comparison of Market Growth, CAGR, 2023-2030

5. REGION-WISE MARKET OUTLOOK TO 2030

- 5.1 Key Findings for Asia Pacific Polycystic Kidney Disease Drugs Market, 2025
- 5.2 Asia Pacific Polycystic Kidney Disease Drugs Market Size Outlook by Type, 2021-2030
- 5.3 Asia Pacific Polycystic Kidney Disease Drugs Market Size Outlook by Application, 2021- 2030
- 5.4 Key Findings for Europe Polycystic Kidney Disease Drugs Market, 2025
- 5.5 Europe Polycystic Kidney Disease Drugs Market Size Outlook by Type, 2021- 2030
- 5.6 Europe Polycystic Kidney Disease Drugs Market Size Outlook by Application, 2021-2030



- 5.7 Key Findings for North America Polycystic Kidney Disease Drugs Market, 2025
- 5.8 North America Polycystic Kidney Disease Drugs Market Size Outlook by Type, 2021- 2030
- 5.9 North America Polycystic Kidney Disease Drugs Market Size Outlook by Application, 2021- 2030
- 5.10 Key Findings for South America Polycystic Kidney Disease Drugs Market, 2025
- 5.11 South America Pacific Polycystic Kidney Disease Drugs Market Size Outlook by Type, 2021- 2030
- 5.12 South America Polycystic Kidney Disease Drugs Market Size Outlook by Application, 2021- 2030
- 5.13 Key Findings for Middle East and Africa Polycystic Kidney Disease Drugs Market, 2025
- 5.14 Middle East Africa Polycystic Kidney Disease Drugs Market Size Outlook by Type, 2021- 2030
- 5.15 Middle East Africa Polycystic Kidney Disease Drugs Market Size Outlook by Application, 2021- 2030

6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030

- 6.1 US Polycystic Kidney Disease Drugs Market Size Outlook and Revenue Growth Forecasts
- 6.2 US Polycystic Kidney Disease Drugs Industry Drivers and Opportunities
- 6.3 Canada Market Size Outlook and Revenue Growth Forecasts
- 6.4 Canada Polycystic Kidney Disease Drugs Industry Drivers and Opportunities
- 6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
- 6.6 Mexico Polycystic Kidney Disease Drugs Industry Drivers and Opportunities
- 6.7 Germany Market Size Outlook and Revenue Growth Forecasts
- 6.8 Germany Polycystic Kidney Disease Drugs Industry Drivers and Opportunities
- 6.9 France Market Size Outlook and Revenue Growth Forecasts
- 6.10 France Polycystic Kidney Disease Drugs Industry Drivers and Opportunities
- 6.11 UK Market Size Outlook and Revenue Growth Forecasts
- 6.12 UK Polycystic Kidney Disease Drugs Industry Drivers and Opportunities
- 6.13 Spain Market Size Outlook and Revenue Growth Forecasts
- 6.14 Spain Polycystic Kidney Disease Drugs Industry Drivers and Opportunities
- 6.16 Italy Market Size Outlook and Revenue Growth Forecasts
- 6.16 Italy Polycystic Kidney Disease Drugs Industry Drivers and Opportunities
- 6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
- 6.18 Rest of Europe Polycystic Kidney Disease Drugs Industry Drivers and Opportunities



- 6.19 China Market Size Outlook and Revenue Growth Forecasts
- 6.20 China Polycystic Kidney Disease Drugs Industry Drivers and Opportunities
- 6.21 India Market Size Outlook and Revenue Growth Forecasts
- 6.22 India Polycystic Kidney Disease Drugs Industry Drivers and Opportunities
- 6.23 Japan Market Size Outlook and Revenue Growth Forecasts
- 6.24 Japan Polycystic Kidney Disease Drugs Industry Drivers and Opportunities
- 6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
- 6.26 South Korea Polycystic Kidney Disease Drugs Industry Drivers and Opportunities
- 6.27 Australia Market Size Outlook and Revenue Growth Forecasts
- 6.28 Australia Polycystic Kidney Disease Drugs Industry Drivers and Opportunities
- 6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
- 6.30 South East Asia Polycystic Kidney Disease Drugs Industry Drivers and Opportunities
- 6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
- 6.32 Rest of Asia Pacific Polycystic Kidney Disease Drugs Industry Drivers and Opportunities
- 6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
- 6.34 Brazil Polycystic Kidney Disease Drugs Industry Drivers and Opportunities
- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina Polycystic Kidney Disease Drugs Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
- 6.38 Rest of South America Polycystic Kidney Disease Drugs Industry Drivers and Opportunities
- 6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
- 6.40 Middle East Polycystic Kidney Disease Drugs Industry Drivers and Opportunities
- 6.41 Africa Market Size Outlook and Revenue Growth Forecasts
- 6.42 Africa Polycystic Kidney Disease Drugs Industry Drivers and Opportunities

7. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET OUTLOOK ACROSS SCENARIOS

- 7.1 Low Growth Case
- 7.2 Reference Growth Case
- 7.3 High Growth Case

8. POLYCYSTIC KIDNEY DISEASE DRUGS COMPANY PROFILES

- 8.1 Profiles of Leading Polycystic Kidney Disease Drugs Companies in the Market
- 8.2 Business Descriptions, SWOT Analysis, and Growth Strategies



8.3 Financial Performance and Key Metrics

Apotex Inc

AstraZeneca Plc

Dr. Reddys Laboratories Ltd

Galapagos NV

Johnson and Johnson

Merck and Co. Inc

Novartis AG

Otsuka Holdings Co. Ltd

Palladio Biosciences Inc

Reata Pharmaceuticals Inc

Regulus Therapeutics Inc

Sanofi SA

Teva Pharmaceutical Industries Ltd

XORTX Therapeutics Inc

9. APPENDIX

- 9.1 Scope of the Report
- 9.2 Research Methodology and Data Sources
- 9.3 Glossary of Terms
- 9.4 Market Definitions
- 9.5 Contact Information



I would like to order

Product name: Polycystic Kidney Disease Drugs Market Size, Trends, Analysis, and Outlook By Type

(ADPKD (Autosomal Dominant Polycystic Kidney Disease), ARPKD (Autosomal

Recessive Polycystic Kidney Disease)), by Region, Country, Segment, and Companies,

2024-2030

Product link: https://marketpublishers.com/r/P7EB0F1B5BF8EN.html

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/P7EB0F1B5BF8EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html



To place an order via fax simply print this form, fill in the information below and fax the completed form to $+44\ 20\ 7900\ 3970$